Micronucleus Frequency and Cervical Cancer Treatment
Author Information
Author(s): Widel M, Jędruś S, Owczarek S, Konopacka M, Lubecka B, Kołosza Z
Primary Institution: Maria Skłodowska-Curie Institute
Hypothesis
The study tests the usefulness of micronucleus assay for predicting tumor radiosensitivity in cervical carcinoma patients.
Conclusion
The increment of micronucleus frequency during radiotherapy may help predict individual responses to treatment in advanced cervical cancer.
Supporting Evidence
- The average increment of micronucleus frequency after 20 Gy was 193% of the spontaneous level.
- A significant correlation was found between micronucleus increment and better tumor local control.
- No significant correlation was observed between in vitro micronucleus frequency and clinical outcomes.
Takeaway
Doctors can use a special test to see how well cervical cancer patients might respond to radiation treatment.
Methodology
The study involved evaluating radiosensitivity using a micronucleus assay on cells from tumor biopsies before and after radiotherapy.
Limitations
The correlation between in vitro and in vivo results was low, and the study focused only on advanced stage cervical carcinoma.
Participant Demographics
Patients with advanced stage (II B–IV B) cervical carcinoma.
Statistical Information
P-Value
P < 0.008 for local control; P < 0.045 for overall survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website